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Ovarian reserveAbstract Aim: Anti-Mu¨llerian hormone (AMH) shows promise as a biomarker of the ovarian
reserve but current assays are insufﬁciently sensitive to allow assessment of this post-chemother-
apy in most women. We have assessed a new highly sensitive AMH assay (Ansh picoAMH) in the
evaluation of ovarian activity in women with very low ovarian reserve after chemotherapy.
Methods: A prospective cohort and an independent validation cohort of premenopausal women
with early breast cancer (eBC) were recruited at the time of diagnosis (combined n = 98), and
ovarian reserve markers 2–5 years later following chemotherapy were assessed in relation to men-
strual activity.
Results: The picoAMH assay had a limit of detection of 7.5 pg/ml. AMH clearly distinguished
women with ongoing menses from those with amenorrhoea at 2 years after diagnosis (mean
522 ± 169 versus 8.9 ± 1.3 pg/ml, P < 0.0001) with high predictive value for continuing menses
or amenorrhoea for the subsequent 3 years. AMH was detectable in more women than using a
previous assay (P = 0.004). Other markers of the ovarian reserve (follicle-stimulating hormone
(FSH), inhibin B) were also of discriminatory value but to lesser extents. This ﬁnding was vali-
dated in a second, independent cohort of women treated for eBC.
Conclusion: The 10-fold increased assay sensitivity showed very clear distinction between groups
based on ovarian activity with excellent prediction of future menses or amenorrhoea. This will
improve assessment of post-chemotherapy ovarian function in women and may aid treatment
decisions.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/3.0/).te, The
Table 1
Characteristics of women in original cohort (cohort 1) and the
validation cohort (cohort 2).
Number in
group
Age
(years)
Endocrine
therapy (n)
Cohort 1
Overall 53 42.5 ± 0.9 45
Ongoing menses 10 35 ± 1.4* 6
Transient amenorrhoea 4 41 ± 2.9 3
Amenorrhoea 25 44.2 ± 0.9 23
No chemotherapy 14 45.8 ± 1.4 13
Cohort 2
Overall 42 43.0 ± 0.9 34
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Adjuvant chemotherapy is a mainstay of treatment of
early breast cancer (eBC) as it results in an improvement
in both disease-free and overall survival rate [1]. Breast
cancer survivors in their reproductive age are now con-
fronted with the long-term consequences of exposure to
these treatments, and therefore quality of life issues
including fertility are becoming more important.
Chemotherapeutic agents can have a profound impact
on ovarian function. They cause a depletion of the follicle
pool in a drug- and dose-dependent manner [2]. Many
women become amenorrhoeic during or after chemother-
apy and chemotherapy-related amenorrhoea (CRA) is
often seen as a sign of ovarian failure [3,4]. Recovery of
menses in some women after chemotherapy illustrates
the limitation of amenorrhoea as a marker of complete
loss of the ovarian reserve; conversely the resumption
of menses may be only brief indicating preservation of
only a very low ovarian reserve.
Anti-Mu¨llerian hormone (AMH) is becoming estab-
lished as a biochemical marker of ovarian reserve
[5–7]. It has been shown to be more sensitive than
inhibin B and follicle-stimulating hormone (FSH) and
ultrasound markers antral follicle count (AFC) and
ovarian volume in assessing chemotherapy-induced
ovarian follicle loss [8]. AMH concentrations showed a
rapid and marked fall during chemotherapy, with
undetectable concentrations in many women after
chemotherapy using the currently available assays
[8–13]. AMH is also undetectable for several years
before the menopause in normal women [14–17]. Thus
current assays are unable to detect AMH in women with
very low ovarian reserve, inadequately distinguishing
such women from those without the likelihood of future
ovarian activity. The diagnosis of ovarian failure has
important therapeutic implications as well as for fertil-
ity, sexual health and non-reproductive e.g. bone health
[18–20], thus its early and reliable diagnosis is central to
the ongoing management of women with breast and
other cancers. Endocrine therapy is often used after che-
motherapy in women with eBC and may complicate
interpretation of conventional diagnosis of ovarian
failure, thus markers of ovarian function which are
more independent of such therapies are required [18].
The main objective of this study was to investigate
the value of a highly sensitive AMH assay in the assess-
ment of ovarian function after chemotherapy in women
with eBC, in comparison with other current markers of
the ovarian reserve.Ongoing menses 8 40.2 ± 1.6 6
Transient amenorrhoea 3 32.3 ± 3.1 2
Amenorrhoea 31 44.9 ± 0.7 26
Data are mean ± sem.
Endocrine therapy consisted of tamoxifen, with additional goserelin in
15 (with one woman receiving only goserelin). Three women received
anastrozole.
* P < 0.05 versus both amenorrhoea and no chemotherapy groups.2. Patients and methods
Two cohorts of premenopausal women with eBC
were recruited from the Edinburgh Breast Unit to a
5-year prospective study of ovarian function (n = 56and n = 42, respectively). All had operable breast cancer
and reported regular menses in the absence of hormonal
contraception. Patients were recruited to the study after
giving informed consent, usually before undergoing
deﬁnitive loco-regional surgery and adjuvant chemo-
therapy for their breast cancer. The ﬁrst cohort was used
to assess the main study questions, and the second for
validation. Chemotherapy regimens for these women
have been previously described and consisted of sequen-
tial anthracycline-CMF or anthracyclines and taxanes in
most [21,22] with 14 women in cohort 1 not given any
chemotherapy; therapeutic decisions were not inﬂuenced
by this study. Both studies received Ethics Committee
approval. Patient characteristics are shown in Table 1.
The proportions of women receiving endocrine therapy
did not diﬀer between groups in either cohort.
Patients were evaluated at 2, 3, 4, and 5 years after
initial diagnosis of breast cancer in cohort 1, and after
1 and 3 years in cohort 2. Visits were scheduled to be
in the early follicular phase (D2-5) if appropriate. Men-
strual data were coded as amenorrhoea when there was
no menstrual bleeding in the preceding 6 months, as
transient amenorrhoea when there was return of menses
after a period of amenorrhoea, or as having ongoing
menses throughout treatment up till the time of analysis.
AMH was assayed using the Ansh labs pico-AMH
ELISA kit (Ansh Catalog no. AL-124, Webster, TX).
For comparison with previous assays, serum samples
taken at 2 years in cohort 1 also analysed using the
Active MIS/AMH ELSIA (Beckman Coulter, Chaska,
MN), sensitivity 0.05 ng/ml [21]. FSH was measured
by enzyme-linked immunosorbent assay (ELISA) [23],
and both intra-assay and inter-assay coeﬃcients of
variation were less than 8%. Inhibin B was measured
as previously described [24], with sensitivity 7.8 pg/ml;
J. Chai et al. / European Journal of Cancer 50 (2014) 2367–2374 2369intra-assay and inter-assay coeﬃcients of variation were
less than 5% and 8%, respectively. Estradiol was mea-
sured by ELISA (Demeditec, Kiel-Wellsee, Germany)
with coeﬃcients of variation <8%.2.1. Statistical analyses
Data are presented as mean ± sem. The primary
analysis was comparison of hormone concentrations
versus menstrual function at 2 years post diagnosis, with
groups compared by ANOVA; in longitudinal analyses
timepoints were compared to data at 2 years using
Dunn’s posthoc test. Proportions of women were com-
pared using Fisher’s exact test. All analyses were per-
formed using SPSS (version 20). A two-tailed value of
P < 0.05 was considered statistically signiﬁcant.3. Results
3.1. Assay characteristics
The lower limit of detection (LLOD: the lowest con-
centration of AMH in a sample that can be detected
with a 95% probability) was determined by serial dilu-
tion of pooled patient serum in two diﬀerent assay
plates. The LLOD was 7.5 pg/ml, in agreement with
the manufacturer’s quoted range of 1.7–11.6 pg/ml.
Inter-assay analytical variation (CV) was 5.6% at
67.7 pg/ml and 2.0% at 185 pg/ml. Intra-assay analytical
variation was less than 10% from 25 pg/ml to 783 pg/ml.0 
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Fig. 1. Serum concentrations of anti-Mu¨llerian hormone (AMH), estradio
women at 2 years after diagnosis of breast cancer. The patient groups were
transient amenorrhoea (TA, n = 4) and those who had not received chemot
menses. Mean ± sem.3.2. Menses after chemotherapy
Amongst the 56 women recruited to the initial cohort,
39 in the chemotherapy group and 14 in the non-chemo-
therapy group remained in the study at 2 years, the key
time point for analysis; the remaining three women had
either withdrawn from the study because of disease recur-
rence or had discontinued follow-up after hysterectomy
and oophorectomy. The majority of patients enrolled in
this study received a combination chemotherapy regimen
that incorporated cyclophosphamide, an anthracycline
and a taxane, as previously described [21]. The 39 women
whohad chemotherapywere subdivided into three groups
according to theirmenstrual pattern over the 2–5 year fol-
lowup period: ongoing menses (n = 10), transient
amenorrhoea (n = 4), and amenorrhoea (n = 25). Ages
of these groups are shown in Table 1. Women with ongo-
ing menses were younger than women who were amen-
orrhoeic (P < 0.05) and the no chemotherapy group
(P < 0.05); the age of the transient amenorrhoea group
was not signiﬁcantly diﬀerent to the others.
3.3. Reproductive hormones after chemotherapy
Serum concentrations of all hormones (AMH, inhi-
bin B, estradiol, and FSH) at 2 years by menstrual func-
tion are shown in Fig. 1.
3.3.1. Anti-Mu¨llerian hormone
AMH clearly discriminated between groups being
detectable in all women with ongoing menses, and0 
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l, inhibin B and follicle-stimulating hormone (FSH) in four groups of
women with on-going menses (n = 10), amenorrhoea (Amen, n = 25),
herapy (NC, n = 14). *P < 0.05; **P < 0.001 versus group with ongoing
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mean at 2 years 522 ± 169 [range 12–1425 pg/ml] versus
8.9 ± 1.3 pg/ml [all <39.6 pg/ml], P < 0.0001. This
marked diﬀerence was sustained with very similar data
at 3, 4 and 5 years with a non-signiﬁcant decline in
AMH through follow-up (Fig. 2). Overall, AMH was
undetectable in only one woman at a single time point
in those with continuing menses, whereas it was unde-
tectable in 81 of 100 samples in the amenorrhoeic group.
Mean AMH was also higher in the ongoing menses
group than in the transient amenorrhoea group
(P < 0.05) but was not diﬀerent to the no chemotherapy
group (P < 0.05). In the groups with ongoing menses
and the no chemotherapy group (i.e. excluding the two
amenorrhoeic groups), the rate of detection of AMH
in women using the picoAMH assay was higher than
using a previous generation assay (20 versus 12 of 24
women; P = 0.004).
Women whose menses returned after a period of
amenorrhoea showed a low but variable pattern of
AMH concentrations. Two women with undetectable
AMH at 2 years showed some recovery during followup,
to concentrations of 55 and 63 pg/ml at 5 years. One of
the women with detectable AMH at 2 years showed a
ﬂuctuating pattern, with AMH becoming undetectable
at 3 and 4 years, but a higher value at 5 years (145 pg/
ml versus 61 pg/ml at 2 years). In the other woman
AMH was close to the limit of detection at 3 years
and was undetectable at 4 and 5 years.0 
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Fig. 2. Anti-Mu¨llerian hormone (AMH) and follicle-stimulating hormone
and in the no chemotherapy group (green) at 2, 3, 4 and 5 years after diag
groups over time. There was a signiﬁcant rise in FSH in the no chemotherap
menses or amenorrhoea groups. Mean ± sem.3.3.2. Inhibin B
Inhibin B concentrations were very low throughout
the period of investigation in all groups (Fig. 1) and
while it tended to be higher in women with continuing
menses, it was undetectable in 5 of 10 of them and there
were no signiﬁcant diﬀerences between groups.3.3.3. Estradiol
Estradiol concentrations mirrored menstrual pattern,
separating women with and without menses (P < 0.0001;
Fig. 1).
The transient amenorrhoea group, although small,
showed comparable patterns to that seen with AMH.
One woman with initially detectable then declining
AMH showed a similar proﬁle for E2, and a woman
with initially undetectable but then rising AMH had
parallel changes in E2. Women in the no chemotherapy
group showed ﬂuctuating E2 concentrations, which were
not signiﬁcantly diﬀerent from either the ongoing men-
ses or amenorrhoeic groups, nor did they vary signiﬁ-
cantly with time.3.3.4. Follicle-stimulating hormone
FSH concentrations were markedly higher in women
with persistent amenorrhoea than in the group with
ongoing menses (P = 0.0001; Fig. 1). These diﬀerences
were observed at all time points up to 5 years, with no
signiﬁcant changes in FSH concentrations in either of
those two groups over that period (Fig. 2). The transient4 5
ter diagnosis 
4 5
(FSH) in women with ongoing menses (red), with amenorrhoea (blue)
nosis. There were no signiﬁcant changes in AMH in any of the three
y group over time (P = 0.02), but no signiﬁcant change in the ongoing
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2 years but marked variability (without statistically sig-
niﬁcant diﬀerences) at subsequent time points. The no
chemotherapy group showed similar FSH concentra-
tions to the ongoing menses group at 2 years but showed
a signiﬁcant rise with time (P = 0.02).
3.4. Discriminatory value of ovarian markers
The ability of the various hormones to discriminate
between women with and without menses was assessed
by receiver operator characteristic (ROC) curve analysis
using data at 2 years (Fig. 3). These gave areas under the
curve (AUC) values of 0.99 for AMH (95% conﬁdence
intervals (CI) 0.97–1.01, P < 0.0001, peak likelihood
ratio (LR) 9.6), 0.93 for E2 (CI 0.83–1.03, P < 0.0001,
peak LR 9.6), 0.74 for inhibin B (CI 0.54–0.94,
P = 0.03, peak LR 2.1) and 0.86 for FSH (CI 0.73–
0.98, P = 0.001, peak LR 7.2). The optimum cut-oﬀ
for AMH was 16.1 pg/ml, giving a sensitivity of 96%
and speciﬁcity of 90%. As this value is close to the limit
of detection of the assay, this result means that a woman
with detectable AMH using this assay is very likely to
have ongoing menses for at least 3 years thereafter
whereas a woman with undetectable AMH does indeed
have no remaining ovarian reserve and will remain
amenorrhoeic.
Includingdata from thewomenwith transient amenor-
rhoea with those with ongoing menses only slightly
reduced the AUC for AMH to 0.97 (peak LR 6.7) andAMH
Estradiol
Inhibin B 
FSH
Fig. 3. Receiver operator characteristic (ROC) curve analysis of anti-
Mu¨llerian hormone (AMH), estradiol, inhibin B and follicle-stimulat-
ing hormone (FSH) in the discrimination of women with and without
amenorrhoea. Areas under the curve (AUC) were AMH: 0.99,
estradiol: 0.93; inhibin: B 0.74 and FSH: 0.86.for E2 to 0.86 (both P < 0.001), whereas the AUC for
inhibin B was reduced to 0.65 and became not signiﬁcant;
AUC for FSH increased slightly to 0.87 (P = 0.0001).3.5. Validation cohort analysis
These ﬁndings were assessed in a second cohort of 42
women with eBC following treatment with chemother-
apy followed up for 3 years as described above. 31 were
amenorrhoeic by 1 year and remained so, eight showed
continuing menses at 1 year, and 3 were amenorrhoeic
at 1 year but had recovered menses by 3 years (Table 1).
AMH concentrations were markedly diﬀerent in the
two groups, mean values 20-fold higher in the women
with ongoing menses than in the amenorrhoea group
(P = 0.0001; Fig. 4). AMH was detectable in all women
with menses at 1 year and remained so at 3 years; while
it was close to the limit of detection in two women
(<20 pg/ml) both had higher concentrations at 3 years
(46 and 155 pg/ml) indicating ongoing recovery from
the eﬀect of chemotherapy. In contrast, AMH was unde-
tectable in 23 of the 31 amenorrhoeic women at 1 year
and very low (<20 pg/ml) in a further 4.
Three women showed return of menses between 1
and 3 years of followup. All had detectable AMH con-
centrations at 1 year, and showed marked rises in
AMH at 3 years (29–567, 750–1405 and 58–357 pg/ml)
although these levels remained very low considering
these women’s age (38, 28 and 29 years, respectively).
Overall mean AMH in women with menses at 3 years
was higher than in the same women at 1 year
(558 ± 196 versus 354 ± 170 pg/ml, P = 0.02, n = 8).4. Discussion
In this prospective study, we examined a panel of
reproductive hormones of ovarian function including
AMH, inhibin B, FSH, and estradiol in eBC survivors,
and used a highly sensitive AMH assay to evaluate the
ovarian reserve in this group of patients. We demon-
strate signiﬁcant diﬀerences in AMH, FSH and estradiol
between women with amenorrhoea compared with those
who continued to menstruate at 2–5 years after diagno-
sis. This is concordant in results with previous data in
which AMH, FSH and estradiol were found to diﬀer
between menstruating and amenorrhoeic women at
1–4 years after chemotherapy [25] although the propor-
tions of women with undetectable AMH were not
shown. That study also suggested a signiﬁcant diﬀerence
in inhibin B level, not conﬁrmed in the present data.
These data thus conﬁrm the value AMH as a marker
of ovarian reserve in this context.
This study also evaluated the predictive potential of
these markers for determining future menstrual status.
AMH was consistently detectable in those with ongoing
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Fig. 4. Anti-Mu¨llerian hormone (AMH) values at 1 and 3 years after diagnosis in the validation cohort of women treated with chemotherapy for
early breast cancer. Red, those with ongoing menses (n = 8); blue, those who were amenorrhoeic (n = 34). *P < 0.001 versus group with ongoing
menses. Mean ± sem.
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analysis. An undetectable level of AMH using this ultra-
sensitive assay at 2 years followup suggests that men-
struation is unlikely to resume whereas a detectable
AMH level suggests that ongoing menstruation is very
likely for at least 3 years thereafter. This contrasts with
this and previous studies using less sensitive assays
which have identiﬁed populations of women with evi-
dence of ovarian function but undetectable AMH
[26,27]. For those women who are pre-menopausal at
diagnosis of an oestrogen receptor (ER) positive breast
cancer, this information would be very helpful in the
clinic. There is good evidence that the sequence of an
aromatase inhibitor after tamoxifen gives superior out-
comes to continuing with tamoxifen, but in women with
functioning ovaries, aromatase inhibitors are ineﬀective
so there is always concern about switching such patients
[28,29]. Therefore patients could be treated with tamox-
ifen initially after completion of chemotherapy, and if at
2 years still had detectable AMH, a switch to an aroma-
tase inhibitor would not be appropriate, whereas it
would be for those with undetectable AMH concentra-
tions. The lack of eﬀect of tamoxifen on AMH [30] sup-
ports this approach. Women who show recovery of
menses after amenorrhoea are an important group in
this context, although they were infrequent in both
cohorts studied here and including them with those with
ongoing menses made little diﬀerence to the discrimina-
tory ability of AMH. They had variably detectable
AMH concentrations, and larger groups of these women
are needed to assess the value of AMH in them.
A substantial proportion of young women retain
ovarian activity after modern adjuvant chemotherapy
for early stage breast cancer [4]. Menstruation is a poor
indicator of fertility potential, but the limited data
indicate that women who retain ovarian function afterchemotherapy can often conceive [31,32], probably
reﬂecting their young age. In normal young women,
low AMH is not associated with reduced fecundity
[33]. Their reproductive lifespan may however be mark-
edly reduced, and AMH may be of value to detect that
and predict remaining duration of potential fertility. In
women with ongoing menstruation AMH was generally
very low (522 ± 169 pg/ml at 2 years) for their age
(mean 35 years), and similar to the no-chemotherapy
group whose mean age was 45 years. These data high-
light the risk of early menopause even in those with
ongoing menses several years after chemotherapy [34];
such women may also be at increased risk of post treat-
ment infertility [35]. There are a paucity of data linking
post-treatment AMH to the clinically important vari-
ables of reproductive lifespan and fertility but the
development of new assays able to detect low levels of
AMH may allow further research to explore these
relationships.
The present analyses are limited particularly by the
numbers of patients included, and by the inclusion only
of women with breast cancer. The number of women
who showed recovery of menses after amenorrhoea
was small and it would be valuable to increase this
group although this is a feature of the age related inci-
dence of breast cancer and the current use of alkylating
agent based chemotherapy. It is unclear whether this
approach will be of value in relation to other diagnoses
and treatments.
In conclusion, these data demonstrate the value of a
more sensitive AMH assay in assessing ovarian function
after chemotherapy, and predicting ovarian activity over
the following years. The improved sensitivity of this
assay also highlights the profound loss of ovarian
reserve in these women. Although these data require
further validation, the measurement of AMH post
J. Chai et al. / European Journal of Cancer 50 (2014) 2367–2374 2373chemotherapy may oﬀer valuable information to both
patients and their clinicians.
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